ACRS - Company ID 0001557746
The table below shows Aclaris Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $2.00M | $3.30M | $1.78M | $1.46M | $4.35M | $2.77M |
| Cost of revenue | $395.00K | $538.00K | $515.00K | $506.00K | $654.00K | $624.00K |
| Gross profit | - | - | - | - | - | - |
| R&D | $15.66M | $13.03M | $11.45M | $11.58M | $5.96M | $8.76M |
Aclaris Therapeutics, Inc. reported annual revenue of $7.83M for fiscal year 2025. That is down 58.2% from $18.72M in fiscal 2024. Over the 9 fiscal years shown, annual revenue grew from $1.68M (FY 2017) to $7.83M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $6.74M |
| $4.87M |
| $5.39M |
| $6.14M |
| $5.65M |
| $4.75M |
| Operating income | -$22.19M | -$17.15M | -$18.41M | -$18.08M | -$10.47M | -$12.85M |
| Income tax | - | - | - | - | - | - |
| Net income | -$19.82M | -$14.61M | -$15.43M | -$15.09M | -$7.59M | -$10.99M |
| EPS (diluted) | -$0.15 | -$0.12 | -$0.13 | -$0.12 | -$0.11 | -$0.15 |